Versant Capital Management Inc Buys 1,608 Shares of Abbott Laboratories (NYSE:ABT)

Versant Capital Management Inc increased its position in Abbott Laboratories ( NYSE:ABT – Free Report ) by 115.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,998 shares of the healthcare product maker’s stock after acquiring an additional 1,608 shares during the quarter.

Versant Capital Management Inc’s holdings in Abbott Laboratories were worth $339,000 at the end of the most recent quarter. Other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp increased its holdings in shares of Abbott Laboratories by 3.



1% in the third quarter. State Street Corp now owns 76,720,429 shares of the healthcare product maker’s stock worth $8,746,896,000 after purchasing an additional 2,323,807 shares during the period. Geode Capital Management LLC increased its stake in Abbott Laboratories by 1.

4% in the 3rd quarter. Geode Capital Management LLC now owns 34,903,198 shares of the healthcare product maker’s stock worth $3,963,974,000 after acquiring an additional 488,764 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Abbott Laboratories by 1.

1% in the 3rd quarter. Wellington Management Group LLP now owns 25,810,977 shares of the healthcare product maker’s stock valued at $2,942,709,000 after acquiring an additional 280,441 shares in the last quarter. Massachusetts Financial Services Co.

MA boosted its position in shares of Abbott Laboratories by 25.6% during the 3rd quarter. Massachusetts Financial Services Co.

MA now owns 13,319,347 shares of the healthcare product maker’s stock valued at $1,518,539,000 after acquiring an additional 2,711,586 shares during the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Abbott Laboratories by 5.6% during the third quarter.

Fisher Asset Management LLC now owns 11,102,204 shares of the healthcare product maker’s stock worth $1,265,762,000 after purchasing an additional 585,915 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth ABT has been the subject of several research analyst reports. Sanford C. Bernstein lifted their target price on shares of Abbott Laboratories from $133.

00 to $138.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Mizuho upped their target price on shares of Abbott Laboratories from $115.

00 to $130.00 and gave the stock a “neutral” rating in a research report on Thursday, October 17th. Evercore ISI raised their price target on Abbott Laboratories to $136.

00 and gave the company a “buy” rating in a research report on Thursday. UBS Group lifted their price target on Abbott Laboratories from $143.00 to $146.

00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Finally, Jefferies Financial Group raised their price objective on Abbott Laboratories from $120.00 to $125.

00 and gave the company a “hold” rating in a report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $131.

57. Abbott Laboratories Trading Up 0.3 % Shares of ABT opened at $113.

44 on Friday. The firm has a fifty day simple moving average of $115.54 and a two-hundred day simple moving average of $112.

07. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $121.

64. The stock has a market capitalization of $196.76 billion, a P/E ratio of 34.

48, a PEG ratio of 2.69 and a beta of 0.73.

The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.

32. Abbott Laboratories ( NYSE:ABT – Get Free Report ) last posted its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.

21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.01.

Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%.

The company had revenue of $10.64 billion for the quarter, compared to analysts’ expectations of $10.55 billion.

During the same period last year, the firm earned $1.14 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.

9% on a year-over-year basis. On average, research analysts anticipate that Abbott Laboratories will post 4.67 EPS for the current year.

Abbott Laboratories Increases Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be paid a $0.59 dividend.

This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th.

This represents a $2.36 dividend on an annualized basis and a yield of 2.08%.

Abbott Laboratories’s dividend payout ratio (DPR) is presently 71.73%. Abbott Laboratories Profile ( Free Report ) Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. Further Reading Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.

com to get the latest 13F filings and insider trades for Abbott Laboratories ( NYSE:ABT – Free Report ). Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter .

.